Asymptomatic lung disease caused by <i>Mycobacterium kansasii</i> as an opportunistic infection in a patient treated with natalizumab for relapsing–remitting multiple sclerosis

Hradílek, Pavel; Zeman, David; Tudik, Ivan; Zapletalová, Olga; Ulmann, Vít

doi:10.1177/1352458513501572

Cited by 10 publications

(5 citation statements)

References 3 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other opportunistic infections have been reported: cryptosporidiosis. TB, aspergilloma, atypical mycobacterial infection, Candida pneumonia, cryptococcal fungemia/meningitis and herpetic meningoencephalitis (51)(52)(53)(54). Screening for latent TB should be considered in patients from endemic countries or otherwise at high risk.…”

Section: Risk Of Infection On Natalizumabmentioning

confidence: 99%

What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature

Pourcher

2020

Revue Neurologique

View full text Add to dashboard Cite

Section: Risk Of Infection On Natalizumabmentioning

confidence: 99%

What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature

Pourcher

2020

Revue Neurologique

View full text Add to dashboard Cite

“…Although this event is unexpected according to the summary of product characteristics, different cases of pulmonary infection during NAT treatment have been described in the literature, such as pulmonary tuberculosis, Mycobacterium intracellulare pneumonia, and a case of Mycobacterium kansasii lung infection. 44 – 46 This evidence suggests a possible role of this agent in opportunistic pulmonary infections, probably due to its immunosuppressive action.…”

Section: Discussionmentioning

confidence: 91%

A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients

Longo

Marrosu

Mancardi

et al. 2018

TCRM

View full text Add to dashboard Cite

PurposeWe performed a pharmacovigilance study of 10 drugs used in patients with relapsing-remitting multiple sclerosis (RR-MS). Our aim was to provide an overview of the safety of these drugs by the evaluation of reported expected and unexpected adverse reactions.Patients and methodsWe collected and analyzed adverse drug reactions from RR-MS patients belonging to four hospitals in three Italian regions, for a period of 24 months.ResultsWe received a total of 411 adverse reactions, of which 84.18% were expected and only 15.82% were unexpected. We found no correlation between the number of reported adverse reactions and the route of administration (injectable/intravenous drugs N=224, oral drugs N=187). However, oral agents have caused a greater number of unexpected moderate-to-severe adverse reactions while, in injectable and infusion therapies, they have been evaluated as mild–moderate adverse reactions.ConclusionOur results underscore the importance of monitoring the safety profile of multiple sclerosis therapies, with particular attention to oral agents that have been introduced later in the clinical practice.

show abstract

“…However, the biologic agents are reported to have something to do with EP 17,18Table 2Summary Of Cases With Respiratory Adverse Events Associated With NatalizumabReferenceRespiratory Adverse EventAgeSexUnderlying DiseasePeripheral Blood EosinophilEosinophilIn BALF11NTM28FRRMSN/AN/A12NTMN/AN/ARRMSN/AN/A13Tb45FRRMSN/AN/A13Tb47FRRMSN/AN/A14PCM46MRRMSN/AN/A15Sarcoidosis38MCDN/AN/A15Sarcoidosis37MCDN/AN/A16Suspected EP41FRRMS490/µL12%Our caseEP39FRRMS5520/µL35% Abbreviations: NTM, nontuberculous mycobacteria; RRMS, relapsing-remitting multiple sclerosis; N/A, not availab...…”

Section: Discussionmentioning

confidence: 99%

<p>Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review</p>

Yasuda

Nagano

Tachihara

et al. 2019

TCRM

View full text Add to dashboard Cite

We herein report the case of a 39-year-old Japanese female with eosinophilic pneumonia associated with natalizumab. The patient with bronchial asthma had multiple sclerosis and was treated using natalizumab. The patient was referred to our department because of a persistent cough. A chest computed tomography (CT) scan revealed bilateral patchy consolidation surrounded by ground-glass opacity. A bronchoalveolar lavage (BAL) was performed. Eosinophil levels in the BAL fluid were increased and the patient was consequently diagnosed as eosinophilic pneumonia associated with natalizumab. Therefore, natalizumab treatment was discontinued. Subsequent chest CT findings showed a remarkable improvement without any treatment.

show abstract

Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing–remitting multiple sclerosis

Cited by 10 publications

References 3 publications

What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature

What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature

A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients

<p>Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review</p>

Contact Info

Product

Resources

About